The results align closely with the Pathfinder phase III trial, which evaluated the efficacy of turoctocog alfa pegol (N8-GP, EHL FVIII) in preventing and treating bleeds in severe hemophilia A. In this trial, patients receiving N8-GP prophylaxis reported a median ABR for overall, joint, spontaneous, and traumatic of 0.00 (mean ABR: 3.70), with >50% experiencing no bleeds during the study. Here, F8 is linked to hemophilia A.